UPDATE 2-Alnylam stock plummets after patient death in hemophilia study

UPDATE 2-Alnylam stock plummets after patient death in hemophilia study


Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died, sending its shares sharply down. A patient suffering from hemophilia A enrolled in a mid-stage study of Alnylam's experimental treatment, fitusiran, died after developing a blood clot, the company said.



from Biotech News